Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
560-06-013 ISMRM Abstract

MRE-Guided Machine Learning Models for Non-Invasive Liver Fibrosis Assessment in MASLD Patients

Primary: Preclinical Animal & in vitro MR - Biology, Models, Methods
Secondary: Analysis Methods - Generative Models
560-06-013 · AI Image Processing · Wednesday, 13 May, 4:55 PM–5:50 PM · Digital Posters Row A
Keywords: MASLD MRE Machine learning (ML)
Accepted
Yifei Huang1, 雯欣 马, Zhiwei Qin2, Songhua Zhan3, Wenli Tan3, Jie Yuan 3
1Department of Radiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
2Shanghai United Imaging Healthcare Co., Ltd, Shanghai, China
3Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Presenting Author: Jie Yuan

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Morisaka H, Motosugi U, Ichikawa S, Nakazawa T, Kondo T, Funayama S, Matsuda M, Ichikawa T, Onishi H. Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging. J Magn Reson Imaging. 2018 May;47(5):1268-1275. doi: 10.1002/jmri.25868. Epub 2017 Oct 14. PMID: 29030995. [doi] [pmid]
2. Marti-Aguado D, Calleja JL, Vilar-Gomez E, Iruzubieta P, Rodríguez-Duque JC, Del Barrio M, Puchades L, Rivera-Esteban J, Perelló C, Puente A, Gomez-Medina C, Escudero-García D, Serra MA, Bataller R, Crespo J, Arias-Loste MT. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4. PMID: 38971533. [doi] [pmid]
3. Nakatsuka T, Tateishi R, Sato M, Hashizume N, Kamada A, Nakano H, Kabeya Y, Yonezawa S, Irie R, Tsujikawa H, Sumida Y, Yoneda M, Akuta N, Kawaguchi T, Takahashi H, Eguchi Y, Seko Y, Itoh Y, Murakami E, Chayama K, Taniai M, Tokushige K, Okanoue T, Sakamoto M, Fujishiro M, Koike K. Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease. Hepatology. 2025 Mar 1;81(3):976-989. doi: 10.1097/HEP.0000000000000904. Epub 2024 May 20. PMID: 38768142; PMCID: PMC11825480. [doi] [pmid]
4. Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, Desai M, Kim SH, Kwong AJ. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. Hepatology. 2023 Jan 1;77(1):256-267. doi: 10.1002/hep.32545. Epub 2022 May 24. PMID: 35477908; PMCID: PMC9613815. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/560-06-013